Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

Li-Nong Ji, Ju-Ming Lu, Xiao-Hui Guo, Wen-Ying Yang, Jian-Ping Weng, Wei-Ping Jia, Da-Jin Zou, Zhi-Guang Zhou, De-Min Yu, Jie Liu, Zhong-Yan Shan, Yu-Zhi Yang, Ren-Ming Hu, Da-Long Zhu, Li-Yong Yang, Li Chen, Zhi-Gang Zhao, Qi-Fu Li, Hao-Ming Tian, Qiu-He Ji, Jing Liu, Jia-Pu Ge, Li-Xin Shi, Yan-Cheng Xu, Li-Nong Ji, Ju-Ming Lu, Xiao-Hui Guo, Wen-Ying Yang, Jian-Ping Weng, Wei-Ping Jia, Da-Jin Zou, Zhi-Guang Zhou, De-Min Yu, Jie Liu, Zhong-Yan Shan, Yu-Zhi Yang, Ren-Ming Hu, Da-Long Zhu, Li-Yong Yang, Li Chen, Zhi-Gang Zhao, Qi-Fu Li, Hao-Ming Tian, Qiu-He Ji, Jing Liu, Jia-Pu Ge, Li-Xin Shi, Yan-Cheng Xu

Abstract

Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for treatment of T2DM across multiple regions in China.

Methods: This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011.

Results: A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454 [0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin (HbA1c) levels (±SD) of 7.67% (±1.58%), 8.21% (±1.91%), and 7.80% (±1.76%), respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM.

Conclusions: Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.

Figures

Figure 1
Figure 1
Mean HbA1c and mean percentage of patients achieving HbA1c <7.0% by duration of type 2 diabetes. HbA1c: glycated hemoglobin, T2DM: type 2 diabetes mellitus.

References

    1. Fu H, Shen SX, Chen ZW, Wang JJ, Ye TT, LaPorte RE, Tajima N. Shanghai, China, has the lowest confirmed incidence of childhood diabetes in the world. Diabetes Care. 1994;17:1206–1208. doi: 10.2337/diacare.17.10.1206.
    1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–1101. doi: 10.1056/NEJMoa0908292.
    1. Zhao D, Zhao F, Li Y, Zheng Z. Projected and observed diabetes epidemics in China and beyond. Curr Cardiol Rep. 2012;14:106–111. doi: 10.1007/s11886-011-0227-9.
    1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853.
    1. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–192. doi: 10.2337/dc08-9026.
    1. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865.
    1. Chinese Diabetes Society. China guideline for type 2 diabetes. Chin J Diabetes Mellitus. 2010;2(suppl 2):6–56.
    1. American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care. 2013;36(suppl 1):S11–S66.
    1. So WY, Raboca J, Sobrepena L, Yoon KH, Deerochanawong C, Ho LT, Himathongkam T, Tong P, Lyubomirsky G, Ko G, Nan H, Chan J. Comprehensive risk assessments of diabetic patients from seven Asian countries: the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes. 2011;3:109–118. doi: 10.1111/j.1753-0407.2011.00115.x.
    1. Editorial. China's major health challenge: control of chronic diseases. Lancet. 2011;378:457. doi: 10.1016/S0140-6736(11)61232-4.
    1. Zhang SL, Chen ZC, Yan L, Chen LH, Cheng H, Ji LN. Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. Chinese Med J (Engl) 2011;124:2461–2468.
    1. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559. doi: 10.4158/EP.15.6.540.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364–1379. doi: 10.2337/dc12-0413.
    1. Tong PC, Ko GT, So WY, Chiang SC, Yang X, Kong AP, Ozaki R, Ma RC, Cockram CS, Chow CC, Chan JC. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes–The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2008;82:346–352. doi: 10.1016/j.diabres.2008.09.006.
    1. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferrera SR, Hancu N, Ilkova H, Ramchandran A, Aschner P. Multifaceted determinants for achieving glycemic control: The international diabetes management practice study (IDMPS) Diabetes Care. 2009;32:227–233.
    1. Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, Ramachandran A. Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS) Diabetes Metab. 2012;38:128–134. doi: 10.1016/j.diabet.2011.09.002.
    1. US National Institute of Diabetes and Digestive and Kidney Diseases. US National Institutes of Health. NIH publication no: Diabetes in America, 2nd edition; pp. 95–1468. [ ]
    1. Bi Y, Zhu D, Cheng J, Zhu Y, Xu N, Cui S, Li W, Cheng X, Wang F, Hu Y, Shen S, Weng J. The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. Clin Ther. 2010;32:973–983. doi: 10.1016/j.clinthera.2010.05.002.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever